{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:07:15Z","timestamp":1792076835523,"version":"4.4.0"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejmech.2021.113201","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T22:14:16Z","timestamp":1611267256000},"page":"113201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":192,"special_numbering":"C","title":["RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic"],"prefix":"10.1016","volume":"213","author":[{"given":"Lei","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minge","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"YuWen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113201_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coviro.2017.01.003","article-title":"Persistent RNA virus infections: do PAMPS drive chronic disease?","volume":"23","author":"McCarthy","year":"2017","journal-title":"Current Opinion in Virology"},{"key":"10.1016\/j.ejmech.2021.113201_bib2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/infdis\/jix046","article-title":"Virucidal activity of world health organization-recommended formulations against enveloped viruses, including Zika, ebola, and emerging coronaviruses","volume":"215","author":"Siddharta","year":"2017","journal-title":"JID (J. Infect. Dis.)"},{"key":"10.1016\/j.ejmech.2021.113201_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ilar\/ilx026","article-title":"Are RNA viruses candidate agents for the next global pandemic?","volume":"58","author":"Carrasco-Hernandez","year":"2017","journal-title":"A\u00a0Review, ILAR Journal"},{"key":"10.1016\/j.ejmech.2021.113201_bib4","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1016\/j.vaccine.2017.04.082","article-title":"AIDS, avian flu, SARS, MERS, ebola, Zika\u2026 what next?","volume":"35","author":"Reperant","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2021.113201_bib5","doi-asserted-by":"crossref","first-page":"138996","DOI":"10.1016\/j.scitotenv.2020.138996","article-title":"Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency","volume":"730","author":"Acter","year":"2020","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.ejmech.2021.113201_bib6","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00259-020-04735-9","article-title":"Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2","volume":"47","author":"Xu","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2021.113201_bib7","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.1002\/jcp.29771","article-title":"Vaccine development and therapeutic design for 2019-nCoV\/SARS-CoV-2: challenges and chances","volume":"235","author":"Ghaebi","year":"2020","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ejmech.2021.113201_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(20)31821-3","article-title":"COVID-19 vaccine trials should seek worthwhile efficacy","volume":"396","author":"Krause","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113201_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113201_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In\u00a0vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113201_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1016\/j.ejmech.2021.113201_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1749-6632.1980.tb27988.x","article-title":"Evolution of RNA viruses","volume":"354","author":"Baltimore","year":"1980","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2021.113201_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrmicro1389","article-title":"Parallels among positive-strand RNA viruses, reverse-transcribing viruses and double-stranded RNA viruses","volume":"4","author":"Ahlquist","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2021.113201_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41594-019-0320-0","article-title":"Conservative transcription in three steps visualized in a double-stranded RNA virus","volume":"26","author":"Cui","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113201_bib16","doi-asserted-by":"crossref","first-page":"8181","DOI":"10.1128\/JVI.77.15.8181-8186.2003","article-title":"Host factors in positive-strand RNA virus genome replication","volume":"77","author":"Ahlquist","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/v11030253","article-title":"Packaging of genomic RNA in positive-sense single-stranded RNA viruses: a complex story","volume":"11","author":"Comas-Garcia","year":"2019","journal-title":"Viruses-Basel"},{"key":"10.1016\/j.ejmech.2021.113201_bib18","first-page":"809","article-title":"The relationship between mutation frequency and replication strategy in positive-sense single-stranded RNA viruses","volume":"277","author":"Th\u00e9baud","year":"2010","journal-title":"Proceedings: Biol. Sci."},{"key":"10.1016\/j.ejmech.2021.113201_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature08283","article-title":"An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA","volume":"461","author":"Maida","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113201_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/v10020076","article-title":"RNA dependent RNA polymerases: insights from structure, function and evolution","volume":"10","author":"Venkataraman","year":"2018","journal-title":"Viruses-Basel"},{"key":"10.1016\/j.ejmech.2021.113201_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/bs.aivir.2016.09.001","article-title":"Nonsegmented negative-sense RNA viruses-structural data bring new insights into nucleocapsid assembly","volume":"97","author":"Jamin","year":"2017","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/v12080835","article-title":"Nucleocapsid structure of negative strand RNA virus","volume":"12","author":"Luo","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2021.113201_bib23","series-title":"Retroviral Vectors in Gene Therapy","author":"Miller","year":"2006"},{"key":"10.1016\/j.ejmech.2021.113201_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000478729","article-title":"Evolution and emergence of pathogenic viruses: past, present, and future","volume":"60","author":"Parvez","year":"2017","journal-title":"Intervirology"},{"key":"10.1016\/j.ejmech.2021.113201_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1473-3099(12)70121-4","article-title":"Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study","volume":"12","author":"Dawood","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113201_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1389202916666150707160613","article-title":"RNA viruses: RNA roles in pathogenesis, coreplication and viral load","volume":"16","author":"Poltronieri","year":"2015","journal-title":"Curr. Genom."},{"key":"10.1016\/j.ejmech.2021.113201_bib27","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.4049\/jimmunol.1800671","article-title":"Influenza A virus infection causes chronic lung disease linked to sites of active viral RNA remnants","volume":"201","author":"Keeler","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2021.113201_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ddstr.2008.01.001","article-title":"Respiratory viral diseases: access to RNA interference therapy","volume":"4","author":"Bitko","year":"2007","journal-title":"Drug Discov. Today Ther. Strat."},{"key":"10.1016\/j.ejmech.2021.113201_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12967-020-02355-3","article-title":"SARS-CoV-2 RNA polymerase as target for antiviral therapy","volume":"18","author":"Buonaguro","year":"2020","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ejmech.2021.113201_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113201_bib31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113201_bib32","doi-asserted-by":"crossref","first-page":"112711","DOI":"10.1016\/j.ejmech.2020.112711","article-title":"The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4161\/rna.8.2.15663","article-title":"RNA virus replication, transcription and recombination","volume":"8","author":"White","year":"2011","journal-title":"RNA Biol."},{"key":"10.1016\/j.ejmech.2021.113201_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fgene.2017.00125","article-title":"Origin and evolution of RNA-dependent RNA polymerase","volume":"8","author":"de Farias","year":"2017","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejmech.2021.113201_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/v10020076","article-title":"RNA dependent RNA polymerases: insights from structure, function and evolution","volume":"10","author":"Venkataraman","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2021.113201_bib36","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0969-2126(97)00261-X","article-title":"Structure of the RNA-dependent RNA polymerase of poliovirus","volume":"5","author":"Hansen","year":"1997","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2021.113201_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/vir.0.81385-0","article-title":"Characterization of the N-terminal domain of classical swine fever virus RNA-dependent RNA polymerase","volume":"87","author":"Xiao","year":"2006","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbrc.2015.08.082","article-title":"Phosphorylation at the N-terminal finger subdomain of a viral RNA-dependent RNA polymerase","volume":"466","author":"Hern\u00e1ndez","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2021.113201_bib39","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s00018-014-1695-z","article-title":"Common and unique features of viral RNA-dependent polymerases","volume":"71","author":"te Velthuis","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113201_bib40","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.3390\/v7082829","article-title":"RNA-dependent RNA polymerases of picornaviruses: from the structure to regulatory mechanisms","volume":"7","author":"Ferrer-Orta","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2021.113201_bib41","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1093\/nar\/gkv838","article-title":"Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses","volume":"43","author":"Lehmann","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib42","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jmv.25761","article-title":"The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase","volume":"92","author":"Lung","year":"2020","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature20594","article-title":"Structural basis of an essential interaction between influenza polymerase and Pol II CTD","volume":"541","author":"Lukarska","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113201_bib44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature15525","article-title":"Crystal structure of the RNA-dependent RNA polymerase from influenza C virus","volume":"527","author":"Hengrung","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113201_bib45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11515-011-1151-5","article-title":"Molecular mechanisms of transcription and replication of the influenza A virus genome","volume":"6","author":"Zhang","year":"2011","journal-title":"Front. Biol."},{"key":"10.1016\/j.ejmech.2021.113201_bib46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41467-019-14246-3","article-title":"Cryo-EM structure of the respiratory syncytial virus RNA polymerase","volume":"11","author":"Cao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.113201_bib47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cell.2015.06.018","article-title":"Structure of the L protein of vesicular stomatitis virus from electron cryomicroscopy","volume":"162","author":"Liang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.113201_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-22328-3","article-title":"Recombinant RNA-dependent RNA polymerase complex of Ebola virus","volume":"8","author":"Tchesnokov","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113201_bib49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2021.113201_bib50","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2174\/1568026043388484","article-title":"Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase","volume":"4","author":"Sharma","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00003495-200969020-00002","article-title":"Antimicrobial strategies: inhibition of viral polymerases by 3\u2019-hydroxyl nucleosides","volume":"69","author":"Deval","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113201_bib52","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1128\/AAC.00186-07","article-title":"Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase","volume":"51","author":"Deval","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01965-17","article-title":"\u03b2-d-N (4)-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome","volume":"92","author":"Urakova","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2021.113201_bib55","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral beta-D-N-4-Hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/JVI.01965-17","article-title":"beta-D-N-4-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome","volume":"92","author":"Urakova","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2021.113201_bib58","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.3390\/v7122934","article-title":"Identification of a new ribonucleoside inhibitor of ebola virus replication","volume":"7","author":"Reynard","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2021.113201_bib59","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.celrep.2017.10.005","article-title":"Signatures of nucleotide analog incorporation by an RNA-dependent RNA polymerase revealed using high-throughput magnetic tweezers","volume":"21","author":"Dulin","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2021.113201_bib60","series-title":"Viral Polymerases, Viral Molecular Machines","first-page":"267","author":"Choi","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113201_bib61","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s00705-017-3444-8","article-title":"Nucleoside analogue 2\u2019-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin","volume":"162","author":"Qu","year":"2017","journal-title":"Arch. Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.01.002","article-title":"Characterization of the activity of 2\u2019-C-methylcytidine against dengue virus replication","volume":"116","author":"Lee","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib63","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.bbrc.2012.10.003","article-title":"Inhibition of norovirus replication by the nucleoside analogue 2\u2019-C-methylcytidine","volume":"427","author":"Rocha-Pereira","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2021.113201_bib64","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1021\/jm0603623","article-title":"Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2\u2019-C-methylcytidine","volume":"49","author":"Pierra","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2\u2019-fluoro-4\u2019-chloromethyl-cytidine triphosphate","volume":"11","author":"Deval","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2021.113201_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154097","article-title":"Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase","volume":"11","author":"Deval","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113201_bib67","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4\u2019-chloromethyl-2\u2019-deoxy-3\u2019,5\u2019-di-O-isobutyryl-2\u2019-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"Wang","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib68","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4\u2032-chloromethyl-2\u2032-deoxy-3\u2032, 5\u2032-di-O-isobutyryl-2\u2032-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"Wang","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib69","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/j.bmcl.2012.03.021","article-title":"Discovery of 4\u2032-azido-2\u2032-deoxy-2\u2032-C-methyl cytidine and prodrugs thereof: a potent inhibitor of Hepatitis C virus replication","volume":"22","author":"Nilsson","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib70","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.bmcl.2005.12.002","article-title":"Synthesis and antiviral activity of 2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication","volume":"16","author":"Clark","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib71","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.00400-06","article-title":"Mechanism of activation of \u03b2-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase","volume":"51","author":"Murakami","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib72","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1128\/JVI.00405-13","article-title":"Inhibition of hepatitis C virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase","volume":"87","author":"Lee","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145409","article-title":"Mericitabine and either Boceprevir or Telaprevir in combination with peginterferon alfa-2a plus Ribavirin for patients with chronic hepatitis C genotype 1 infection and prior null response: the randomized DYNAMO 1 and DYNAMO 2 studies","volume":"11","author":"Wedemeyer","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113201_bib74","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.24788","article-title":"Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)","volume":"55","author":"Guedj","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.113201_bib75","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113201_bib76","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1086\/656774","article-title":"RG7128 alone or in combination with pegylated interferon-\u03b12a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients","volume":"202","author":"Le Pogam","year":"2010","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113201_bib77","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of beta-D-2\u2019-deoxy-2\u2019-fluoro-2\u2019-C-methylcytidine involves a second metabolic pathway leading to beta-D-2\u2019-deoxy-2\u2019-fluoro-2\u2019-C-methyluridine 5\u2019-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib78","doi-asserted-by":"crossref","first-page":"29812","DOI":"10.1074\/jbc.M705274200","article-title":"Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2\u2019-Deoxy-2\u2019-fluoro-2\u2019-C-methylcytidine (PSI-6130) and identification of a novel active 5\u2019-triphosphate species","volume":"282","author":"Ma","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib79","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-d-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib80","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1128\/AAC.01262-12","article-title":"Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects","volume":"57","author":"Denning","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib81","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib82","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2021.113201_bib83","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1517\/17460441.2015.1094051","article-title":"The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C","volume":"10","author":"Gentile","year":"2015","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113201_bib84","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1038\/s41598-017-09797-8","article-title":"Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae","volume":"7","author":"Ferreira","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113201_bib85","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1016\/j.celrep.2016.08.038","article-title":"Zika virus disrupts phospho-TBK1 localization and mitosis in human neuroepithelial stem cells and radial glia","volume":"16","author":"Onorati","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2021.113201_bib86","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1038\/s41598-017-06612-2","article-title":"Evaluation of Sofosbuvir (\u03b2-D-2\u2019-deoxy-2\u2019-\u03b1-fluoro-2\u2019-\u03b2-C-methyluridine) as an inhibitor of Dengue virus replication<sup\/>","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113201_bib87","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3851\/IMP2733","article-title":"Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938","volume":"19","author":"Guedj","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2021.113201_bib88","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2021.113201_bib89","series-title":"Sofosbuvir Protects Human Brain Organoids against SARS-CoV-2","author":"Mesci","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113201_bib90","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1021\/acs.jmedchem.9b00143","article-title":"Synthesis and anti-HCV activities of 4\u2032-fluoro-2\u2032-substituted uridine triphosphates and nucleotide prodrugs: discovery of 4\u2032-fluoro-2\u2032-C-methyluridine 5\u2032-phosphoramidate prodrug (AL-335) for the treatment of hepatitis C infection","volume":"62","author":"Wang","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204974","article-title":"Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects","volume":"13","author":"McClure","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113201_bib92","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/hep.30527","article-title":"JNJ-4178 (AL-335, odalasvir, and simeprevir) for 6 or 8 Weeks in hepatitis C virus-infected patients without cirrhosis: omega-1","volume":"69","author":"Zeuzem","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.113201_bib93","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1021\/acs.jmedchem.6b00382","volume":"59","author":"Jonckers","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib94","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2014.921680","article-title":"Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus","volume":"23","author":"Gentile","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2021.113201_bib95","first-page":"S355","article-title":"ALS-2200, a novel once-daily nucleotide hcv polymerase inhibitor, demonstrated potent antiviral activity in treatment-nave patients with compensated cirrhosis or genotype 2-4 chronic hepatitis c","volume":"58","author":"Marcellin","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib96","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0165-6147(84)90534-0","article-title":"Deuterium isotope effects in studies of drug metabolism","volume":"5","author":"Foster","year":"1984","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2021.113201_bib97","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/S0168-8278(15)30181-1","article-title":"LP27: ACH-3422, A novel nucleotide prodrug inhibitor of HCV NS5B polymerase","volume":"62","author":"Gane","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib98","doi-asserted-by":"crossref","first-page":"7366","DOI":"10.1021\/bi4013287","article-title":"Potent inhibition of the C\u2013P lyase nucleosidase PhnI by immucillin-A triphosphate","volume":"52","author":"Kamat","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.113201_bib99","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113201_bib100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.05.013","article-title":"Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters","volume":"156","author":"Westover","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib101","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2021.113201_bib102","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1098612X19825701","article-title":"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis","volume":"21","author":"Pedersen","year":"2019","journal-title":"J.\u00a0Feline Med. Surg."},{"key":"10.1016\/j.ejmech.2021.113201_bib103","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vetmic.2018.04.026","article-title":"The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies","volume":"219","author":"Murphy","year":"2018","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.ejmech.2021.113201_bib104","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acsmedchemlett.8b00586","article-title":"The ProTide prodrug technology: where next?","volume":"10","author":"Alanazi","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113201_bib105","doi-asserted-by":"crossref","first-page":"112527","DOI":"10.1016\/j.ejmech.2020.112527","article-title":"A\u00a0promising antiviral candidate drug for the COVID-19 pandemic: a mini-review of remdesivir","volume":"201","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib106","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113201_bib107","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/jac\/dkaa239","article-title":"Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19","volume":"75","author":"Tempestilli","year":"2020","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib108","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113201_bib109","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","article-title":"Advantages of the parent nucleoside GS-441524 over remdesivir for covid-19 treatment","volume":"11","author":"Yan","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113201_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227104","article-title":"Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus","volume":"15","author":"Good","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113201_bib111","first-page":"12","article-title":"Safety, pharmacokinetics, and antiviral activity of AT-527, a novel purine nucleotide prodrug","volume":"vol. 63","author":"Berliba","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113201_bib112","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2013.11.008","article-title":"Chutes and ladders in hepatitis C nucleoside drug development","volume":"102","author":"Coats","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib113","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(08)60069-0","article-title":"Potent antiviral activity of second generation nucleoside inhibitors, IDX102 and IDX184, in HCV-infected chimpanzees","volume":"48","author":"Standring","year":"2008","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib114","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0168-8278(10)61204-4","article-title":"Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) in treatment - naive HCV genotype 1- infected subjects","volume":"52","author":"Lalezari","year":"2010","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib115","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2021.113201_bib116","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib117","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2015.08.015","article-title":"Ebola virus dynamics in mice treated with favipiravir","volume":"123","author":"Madelain","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib118","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.ejmech.2021.113201_bib119","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","volume":"108","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2021.113201_bib120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2217\/fvl-2018-0166","article-title":"Ribavirin: pharmacology, multiple modes of action and possible future perspectives","volume":"14","author":"Nystr\u00f6m","year":"2019","journal-title":"Future Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib121","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2010.11.002","article-title":"Combination of \u03b1-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in\u00a0vitro and in\u00a0vivo","volume":"89","author":"Chang","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib122","first-page":"238","article-title":"Ribavirin in the treatment of severe acute respiratory syndrome (SARS)","volume":"61","author":"van Vonderen","year":"2003","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.ejmech.2021.113201_bib123","doi-asserted-by":"crossref","first-page":"106114","DOI":"10.1016\/j.ijantimicag.2020.106114","article-title":"Ribavirin therapy for severe COVID-19: a retrospective cohort study","volume":"56","author":"Tong","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2021.113201_bib124","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113201_bib125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.128.1.263","article-title":"Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers","volume":"128","author":"Chiou","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2021.113201_bib126","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3851\/IMP3212","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2018","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2021.113201_bib127","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial","volume":"219","author":"Finberg","year":"2019","journal-title":"JID (J. Infect. Dis.)"},{"key":"10.1016\/j.ejmech.2021.113201_bib128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","article-title":"Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference","volume":"167","author":"Beigel","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib129","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1128\/JVI.02628-05","article-title":"Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus","volume":"80","author":"Le Pogam","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bmcl.2003.10.023","article-title":"Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives","volume":"14","author":"Beaulieu","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib131","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/nar\/gkh160","article-title":"Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template\/primer substrate","volume":"32","author":"McKercher","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.113201_bib132","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1021\/jm060269e","article-title":"Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109","volume":"49","author":"Hirashima","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib133","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1021\/jm040134d","article-title":"Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells","volume":"47","author":"Beaulieu","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib134","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1016\/j.bmcl.2006.07.074","article-title":"Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds","volume":"16","author":"Beaulieu","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib135","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1016\/S0168-8278(09)61056-4","article-title":"SAFETY, pharmacokinetics and antiviral effect OF BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment IN patients with chronic hepatitis C","volume":"50","author":"Larrey","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib136","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/508776","article-title":"Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization","volume":"43","author":"Snape","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113201_bib137","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bmcl.2008.12.068","article-title":"Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase","volume":"19","author":"Stansfield","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib138","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/jm1013105","article-title":"Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase","volume":"54","author":"Narjes","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib139","first-page":"1568","article-title":"Safety and antiviral activity of NS5B polymerase inhibitor MK-3281","volume":"1","author":"Brainard","year":"2009","journal-title":"Treatment-Na\u00efve Genotype A"},{"key":"10.1016\/j.ejmech.2021.113201_bib140","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1128\/AAC.04383-14","article-title":"Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis","volume":"59","author":"Zeuzem","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib141","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1128\/JVI.77.13.7575-7581.2003","article-title":"Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme","volume":"77","author":"Love","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113201_bib142","doi-asserted-by":"crossref","first-page":"39260","DOI":"10.1074\/jbc.M506407200","article-title":"Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase","volume":"280","author":"Kukolj","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib143","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/AAC.02495-13","article-title":"Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase","volume":"58","author":"Lemm","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib144","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.2015.1059820","article-title":"Beclabuvir for the treatment of hepatitis C","volume":"24","author":"Gentile","year":"2015","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2021.113201_bib145","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.2015.3860","article-title":"Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection","volume":"313","author":"Poordad","year":"2015","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2021.113201_bib146","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jvh.12372","article-title":"A\u00a0randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon\/ribavirin for HCV genotype 1","volume":"22","author":"Tatum","year":"2015","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.ejmech.2021.113201_bib147","doi-asserted-by":"crossref","first-page":"9489","DOI":"10.1074\/jbc.M209397200","article-title":"Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition","volume":"278","author":"Wang","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib148","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.str.2004.05.024","article-title":"The crystal structure of the RNA-dependent RNA polymerase from human rhinovirus: a dual function target for common cold antiviral therapy","volume":"12","author":"Love","year":"2004","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2021.113201_bib149","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.02052-12","article-title":"Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase","volume":"57","author":"Fenaux","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib150","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1586\/14787210.2014.945432","article-title":"GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection","volume":"12","author":"Gentile","year":"2014","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.ejmech.2021.113201_bib151","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/AAC.01599-08","article-title":"Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"53","author":"Shi","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib152","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1021\/jm8014537","volume":"52","author":"Li","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib153","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bmcl.2003.10.067","article-title":"Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides","volume":"14","author":"Chan","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib154","doi-asserted-by":"crossref","first-page":"111747","DOI":"10.1016\/j.ejmech.2019.111747","article-title":"Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors","volume":"184","author":"Hassan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2009.03.015","article-title":"Evaluation of VCH-759 monotherapy in hepatitis C infection","volume":"51","author":"Cooper","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib156","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.1016\/S0168-8278(08)60856-9","article-title":"Results of a safety, tolerability and pharmacokinetic phase I study of VCH-916, a novel polymerase inhibitor for HCV, following single ascending doses in healthy volunteers","volume":"48","author":"Proulx","year":"2008","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib157","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.05438-11","article-title":"Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir","volume":"56","author":"Yi","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib158","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/S0168-8278(09)60937-5","article-title":"935 identification and characterization of VCH-222, a novel potent and selective non-nucleoside HCV polymerase inhibitor","volume":"50","author":"Bedard","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib159","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/S0168-8278(09)60942-9","article-title":"Safety, toperability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals","volume":"50","author":"Cooper","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib160","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.1021\/jm0401255","article-title":"Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors","volume":"47","author":"Gopalsamy","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib161","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.bmcl.2006.01.105","article-title":"Design and synthesis of 2,3,4,9-tetrahydro-1H-carbazole and 1,2,3,4-tetrahydro-cyclopenta[b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase","volume":"16","author":"Gopalsamy","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib162","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bmcl.2005.08.114","article-title":"Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase","volume":"16","author":"Gopalsamy","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib163","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.1021\/jm401266k","article-title":"Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B","volume":"56","author":"Schoenfeld","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib164","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/acs.jmedchem.7b01630","article-title":"Synthesis and biological characterization of aryl uracil inhibitors of hepatitis C virus NS5B polymerase: discovery of ABT-072, a trans-stilbene analog with good oral bioavailability","volume":"61","author":"Randolph","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib165","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/acs.jmedchem.7b01630","article-title":"Synthesis and biological characterization of aryl uracil inhibitors of hepatitis C virus NS5B polymerase: discovery of ABT-072, a trans-Stilbene analog with good oral bioavailability","volume":"61","author":"Randolph","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib166","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2013.02.009","article-title":"A\u00a0phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450\/r, ABT-072) and ribavirin in IL28B C\/C patients with chronic hepatitis C genotype 1","volume":"59","author":"Lawitz","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib167","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1016\/j.bmcl.2012.04.017","article-title":"Identification of aryl dihydrouracil derivatives as palm initiation site inhibitors of HCV NS5B polymerase","volume":"22","author":"Liu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib168","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In\u00a0vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor","volume":"59","author":"Kati","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib169","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/17460441.2017.1322955","article-title":"Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection","volume":"12","author":"El Kassas","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113201_bib170","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1016\/j.bmcl.2009.05.091","article-title":"Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase","volume":"19","author":"Shaw","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib171","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1021\/jm050855s","article-title":"3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase","volume":"49","author":"Tedesco","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib172","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61057-6","article-title":"1055 antiviral activity OF ANA598, a potent NON-nucleoside polymerase inhibitor, IN chronic hepatitis C patients","volume":"50","author":"Lawitz","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib173","unstructured":"I. Gaultier, D. Cohen, E. Dumas, L. Larsen, T. Podsadecki, B. Bernstein, 12-week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon\u00a0+ ribavirin, following 3-day monotherapy in genotype 1 HCV infected treatment-naive subjects, 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL), 17-20 February 2011, Thailand."},{"key":"10.1016\/j.ejmech.2021.113201_bib174","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S0168-8278(07)62192-8","article-title":"GSK625433; a novel and highly potent inhibitor of the HCV NS5B polymerase","volume":"46","author":"Gray","year":"2007","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib175","first-page":"1166A","article-title":"In\u00a0vitro activity and pharmacological properties of IDX375, a novel HCV non-nucleoside inhibitor","volume":"48","author":"Standring","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.113201_bib176","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1128\/AAC.00451-12","article-title":"First-in-human study of the pharmacokinetics and antiviral activity of IDX375, a novel nonnucleoside hepatitis C virus polymerase inhibitor","volume":"56","author":"de Bruijne","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113201_bib177","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1016\/S0168-8278(16)00681-4","article-title":"CC-31244, A novel, pan-genotypic, potent NS5B non-nucleoside polymerase inhibitor for the treatment of chronic hepatitis C","volume":"64","author":"Jacobson","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib178","doi-asserted-by":"crossref","first-page":"S720","DOI":"10.1016\/S0168-8278(17)31924-4","article-title":"Phase 1 study assessing the safety, pharmacokinetics, and antiviral activity of CC-31244, a pan-genotypic, potent non-nucleoside NS5B polymerase inhibitor for the treatment of hepatitis C virus infection","volume":"66","author":"Lee","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113201_bib179","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00238-08","article-title":"Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor","volume":"52","author":"Howe","year":"2008","journal-title":"HCV-796, Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.ejmech.2021.113201_bib180","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hep.22717","article-title":"HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in\u00a0vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus","volume":"49","author":"Kneteman","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.113201_bib181","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MCG.0b013e318178d91f","article-title":"Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor","volume":"43","author":"Feldstein","year":"2009","journal-title":"J.\u00a0Clin. Gastroenterol."},{"key":"10.1016\/j.ejmech.2021.113201_bib182","first-page":"255A","article-title":"Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCVNS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects","volume":"46","author":"Bavisotto","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.113201_bib183","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.virol.2012.03.025","article-title":"Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a","volume":"429","author":"Wong","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2021.113201_bib184","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.bmcl.2010.02.054","article-title":"Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides","volume":"20","author":"Cheng","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113201_bib185","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1038\/s41598-020-66440-9","article-title":"Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic","volume":"10","author":"J\u00e1come","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113201_bib186","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113201_bib187","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.ijbiomac.2020.09.098","article-title":"Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach","volume":"163","author":"Parvez","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2021.113201_bib188","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.cmi.2020.06.025","article-title":"Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting","volume":"26","author":"Hughes","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejmech.2021.113201_bib189","doi-asserted-by":"crossref","first-page":"174508","DOI":"10.1063\/1.4873352","article-title":"Effect of quantum nuclear motion on hydrogen bonding","volume":"140","author":"McKenzie","year":"2014","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.ejmech.2021.113201_bib190","series-title":"Deuterium A Nucleoside Analogue and Preparation Method and Use Thereof. CN111233929A","author":"Wen","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113201_bib191","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1021\/acs.jmedchem.0c00935","article-title":"Synthesis and anti-HCV activity of sugar-modified guanosine analogues: discovery of AL-611 as an HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C","volume":"63","author":"Wang","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113201_bib192","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1021\/acs.jmedchem.9b00781","article-title":"Design, synthesis, and anti-RNA virus activity of 6\u2032-fluorinated-aristeromycin analogues","volume":"62","author":"Yoon","year":"2019","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421000507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421000507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:25:36Z","timestamp":1759328736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421000507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":192,"alternative-id":["S0223523421000507"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113201","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113201"}}